Product Description
Doxercalciferol is used to treat secondary hyperparathyroidism (a condition in which the body produces too much parathyroid hormone [PTH; a natural substance needed to control the amount of calcium in the blood]) in certain people with chronic kidney disease and in those treated with dialysis (medical treatment to clean the blood when the kidneys are not working properly). Doxercalciferol is in a class of medications called vitamin D analogs. It works by helping the body to use more of the calcium found in foods or supplements and by regulating the body's production of parathyroid hormone. (Sourced from: https://medlineplus.gov/druginfo/meds/a616043.html)
Mechanisms of Action: VDR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Injection
FDA Designation: None *
Approval Status: Approved
Approved Countries: Canada | Chile | Colombia | Egypt | India | Mexico | Taiwan | United States
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Chile, China, United States
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: Hyperparathyroidism, Secondary|Kidney Diseases|Kidney Failure, Chronic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| LPS14314 | P3 |
Active, not recruiting |
Hyperparathyroidism, Secondary|Kidney Failure, Chronic |
2025-11-12 |
49% |
| CTR20211616 | P3 |
Completed |
Hyperparathyroidism, Secondary|Kidney Diseases |
2023-11-30 |